Please assess the completion status of the following clinical trial:

Trial Title: Methotrexate in Metastatic Colorectal Cancer With MSH2 Deficiency

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Confirmed diagnosis of metastatic or locally recurrent colorectal carcinoma~* Aged 18 years or older~* Paraffin embedded histological material available for analysis~* Either confirmed loss of expression of MSH2 on immunohistochemistry IHC or confirmed mutation in MSH2 on gene sequencing~* Life expectancy of \> 3 months~Exclusion Criteria:~* Previous treatment with methotrexate, either for malignant or non-malignant disease, except when methotrexate was given at low dose with other drugs to modify their effects~* Concomitant uncontrolled medical conditions~* Concomitant metastatic malignancy apart from non-melanotic skin cancers and carcinoma in situ of the uterine cervix in the last 10 years~* Any contraindication to treatment with methotrexate (as this will affect safety)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).